BETHESDA, Md.–(BUSINESS WIRE)–ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced the appointment of Peter Greenleaf to its board of directors. Mr. Greenleaf, a seasoned industry executive with nearly 30 years of experience leading successful life sciences companies, is currently the president, chief executive officer and member of the Board of Aurinia Pharmaceuticals, Inc., a fully integrated, publicly traded biopharmaceutical company advancing innovative treatments for autoimmune diseases.
“Peter has an extensive track record in building and leading biopharmaceutical companies from early-stage through development and commercialization, and we very much welcome him to our board of directors,” said John Doux, M.D., MBA, Chairman of the Board and independent director. “Peter’s depth of expertise will be instrumental to supporting the next phase of our company as it advances two clinical stage programs, an expanding pipeline of assets, and a maturing assessment of corporate and portfolio strategies.”
“ValenzaBio is building a best-in-class suite of programs aimed at offering clear advantages to treating autoimmune and inflammatory conditions for patients, caregivers and physicians,” said Mr. Greenleaf. “With clinical readouts on the horizon and a compelling set of programs following closely behind, I’m excited to partner with this talented management team and the Board, as they work to bring meaningful new treatments to patients in need.”
Mr. Greenleaf has served the president, chief executive officer and member of the Board of Aurinia Pharmaceuticals, Inc., since April 2019. Prior to Aurinia, he held a number of chief executive roles, including at Cerecor, Inc., Sucampo Pharmaceuticals, Inc., and Histogenics Corporation. Earlier, Mr. Greenleaf held roles at Medlmmune LLC, the global biologics arm of AstraZeneca, where he most recently served as president. Before that, he was senior vice president, commercial operations of MedImmune, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson & Johnson) and Boehringer Mannheim (now Roche Holdings). Mr. Greenleaf earned his MBA from St. Joseph’s University and B.S. from Western Connecticut State University.
About ValenzaBio, Inc.
ValenzaBio is a privately held biopharmaceutical company developing safe and effective therapies for autoimmune and inflammatory diseases. The company is advancing a pipeline of differentiated monoclonal antibodies with best-in-class properties, targeting clinically validated mechanisms of action, to provide improved treatment options for patients. VB421 is a potential best-in-class mAb targeting IGF-1R, which plays a central role in the pathogenesis of thyroid eye disease (TED). In addition to VB421, ValenzaBio’s first program in clinic, VB119, continues to actively enroll trials in renal autoimmune indications. A third program, VB517 is expected to begin clinical trials in 2023. ValenzaBio is based in Bethesda, MD.
For more information, please visit www.valenzabiotech.com.